These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3457102)

  • 21. Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report.
    Pellier I; Leboucher B; Rachieru P; Ifrah N; Rialland X
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):837-9. PubMed ID: 17164656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
    Patterson D; Kravtsova VM; Petrova EM; Zabelina TS; Balaian LN
    Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with the use of cytosine arabinoside in adult acute leukaemia.
    Brodie GN; Penny R
    Med J Aust; 1970 Mar; 1(13):635-7. PubMed ID: 5267173
    [No Abstract]   [Full Text] [Related]  

  • 24. High-dose cytosine arabinoside in the treatment of resistant acute leukemia.
    Takaku F; Urabe A; Mizoguchi H; Yamada O; Wakabayashi Y; Miura Y; Sakamoto S; Yoshida M; Miwa S; Asano S
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):144-9. PubMed ID: 3859929
    [No Abstract]   [Full Text] [Related]  

  • 25. Central nervous system toxicity of high-dose systemic cytosine arabinoside.
    Lazarus HM; Herzig RH; Herzig GP; Phillips GL; Roessmann U; Fishman DJ
    Cancer; 1981 Dec; 48(12):2577-82. PubMed ID: 7306918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.
    Preisler HD; Raza A; Barcos M; Azarnia N; Larson R; Walker I; Browman M; Grunwald H; D'Arrigo P; Doeblin T
    J Clin Oncol; 1987 Jan; 5(1):75-82. PubMed ID: 3806162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study.
    Winkelman MD; Hines JD
    Ann Neurol; 1983 Nov; 14(5):520-7. PubMed ID: 6651239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes.
    Curtis JE; Messner HA; Minden MD; Minkin S; McCulloch EA
    J Clin Oncol; 1987 Apr; 5(4):532-43. PubMed ID: 3549988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced toxicities associated with high-dose cytosine arabinoside infusions.
    Graves T; Hooks MA
    Pharmacotherapy; 1989; 9(1):23-8. PubMed ID: 2922357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukaemia.
    Jensen MK; Ahlbom G
    Scand J Haematol; 1985 Mar; 34(3):261-3. PubMed ID: 3992192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary evaluation of cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in acute leukemia of children.
    Freedman MH; Finklestein JZ; Gilchrist GS; Hammond GD; Higgins GR; Hyman CB; Shore NA; Williams KO; Karon MR
    Cancer Chemother Rep; 1969 Oct; 53(5):299-303. PubMed ID: 5270583
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical use of cytosine arabinoside in infancy. I. Cytosine arabinoside in the treatment of acute leukosis].
    Masi M; Vivarelli F; Paolucci P; Vecchi V
    Minerva Pediatr; 1975 Sep; 27(28):1539-50. PubMed ID: 1101022
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
    Satou Y; Kubota T; Yonekura S; Noguchi K; Oobayashi Y; Nagao T; Arimori S
    Tokai J Exp Clin Med; 1986 Oct; 11(4):249-54. PubMed ID: 3617109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside.
    Frick J; Ritch PS; Hansen RM; Anderson T
    J Clin Oncol; 1984 May; 2(5):365-8. PubMed ID: 6726293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [High doses of cytosine arabinoside in the treatment of refractory leukemia].
    Klener P; Háber J; Kolesková E
    Sb Lek; 1987 Sep; 89(8-9):271-5. PubMed ID: 3478794
    [No Abstract]   [Full Text] [Related]  

  • 38. The neurotoxicity of high-dose cytosine arabinoside is age-related.
    Gottlieb D; Bradstock K; Koutts J; Robertson T; Lee C; Castaldi P
    Cancer; 1987 Oct; 60(7):1439-41. PubMed ID: 3476181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
    Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
    J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.